Loading provider…
Loading provider…
Medical Oncology Physician in Charleston, SC
NPI: 1437233533Primary Practice Location
MUSC MEDICAL CENTER
25 Courtenay Dr, Charleston, SC
Primary Employer
MUSC Physicians
muschealth.org
HQ Phone
Get MD Albert's Phone Numberphone_androidMobile
Get MD Albert's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
MO State Medical License
SC State Medical License
SC State Medical License
2021 - 2027
FL State Medical License
2017 - 2023
MO State Medical License
2008 - 2018
TN State Medical License
2001 - 2010
NC State Medical License
1999 - 2003
TX State Medical License
1995 - 2001

American Board of Internal Medicine
Medical Oncology
Duke University Hospital
Fellowship • Hematology and Medical Oncology
1997 - 2000
Washington University/B-JH/SLCH Consortium
Residency • Internal Medicine
1993 - 1996
UT Southwestern Medical Center
utsouthwestern.edu
Medical School
Until 1993
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 38 | 70 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 36 | 66 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 29 | 29 |
Novel targets in esophageal and gastric cancer: beyond antiangiogenesis
Authors: Lee, Wooin, Patel, Jignesh H, Lockhart, A Craig
Journal: Expert Opin Investig Drugs
Ras inhibition and the survival benefit favoring zoledronic acid compared with denosumab in patients with multiple myeloma.
Authors: Steven Sorscher
Publication Date: 2011-06-08
Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression.
Authors: Timothy Ley, Matthew Strand
Publication Date: 2018-10-31
Lead Sponsor: Washington University School of Medicine
Collaborators: United States Department of Defense, Rising Tide Foundation
Intervention / Treatment: BIOLOGICAL: Mammaglobin-A DNA Vaccine, PROCEDURE: Optional biopsy
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Laboratory Biomarker Analysis
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Biospecimen Collection, PROCEDURE: Computed Tomography, DRUG: Irinotecan Hydrochloride, DRUG: Berzosertib, PROCEDURE: Biopsy Specimen